Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
GnT-IVA CRISPR Activation Plasmid (h): sc-407146-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- GnT-IVA CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- GnT-IVA CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by GnT-IVA CRISPR Activation Plasmid (h) and GnT-IVA CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the MGAT4A transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: GnT-IVA Antibody (M-71): sc-100785
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GnT-IVA CRISPR Activation Plasmid (h) | sc-407146-ACT | 20 µg | $397.00 |
Human MGAT4A encodes N-acetylglucosaminyltransferase IVa (GnT-IVA), a Golgi-resident glycosyltransferase that adds β1,4-linked N-acetylglucosamine branches to complex N-glycans. This enzymatic step contributes to N-glycan branching that can modulate protein folding and trafficking, receptor residency at the cell surface, and downstream signaling dynamics. MGAT4A-dependent glycosylation interfaces with broader glycan biosynthesis networks that influence cell–cell interactions, nutrient sensing, and membrane receptor regulation. Dysregulated N-glycosylation and altered branching patterns involving MGAT4A have been studied in contexts of metabolic dysfunction and cancer-associated glycophenotypes, supporting its use in mechanistic pathway and biomarker-discovery research.
GnT-IVA CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous MGAT4A expression without altering the underlying DNA sequence.
GnT-IVA CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the MGAT4A locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the MGAT4A transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous GnT-IVA expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native MGAT4A locus and enabling the study of GnT-IVA-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of GnT-IVA pathway restoration in tumor cells with silenced or reduced MGAT4A expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.